Medical Corporation Association Shinanokai Shinanozaka Clinic
Welcome,         Profile    Billing    Logout  
 3 Trials 
15 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Contact, See Central
DESTINY-Breast05, NCT04622319 / 2020-003982-20: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Calendar Jan 2024 - Dec 2024: Data from DESTINY-Breast05 trial for HER2+ post neo-adjuvant breast cancer
Calendar Jan 2024 - Dec 2024: Acceptance of of regulatory submission for HER2+ post neo-adjuvant breast cancer (DESTINY-Breast05 trial)
Active, not recruiting
3
1600
Europe, Canada, Japan, US, RoW
DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1)
Daiichi Sankyo, Inc., AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI)
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
12/25
12/30
NCT05547087: A Dose Finding Study of VN-0200

Completed
2
342
Japan
VN-0200
Daiichi Sankyo
Respiratory Syncytial Virus Infections
04/23
02/24
HERTHENA-PanTumor01, NCT06172478: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
2
400
Japan, US, RoW
HER3-DXd, Patritumab Deruxtecan, U3-1402
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
06/25
04/26
NCT04703322: A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Recruiting
2
21
Japan
Pexidartinib, TURALIO™, PLX3397
Daiichi Sankyo Co., Ltd.
Tenosynovial Giant Cell Tumor
02/25
11/26
IDeate-Pantumor 01, NCT04145622: Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Recruiting
1/2
250
Japan, US
Ifinatamab deruxtecan (I-DXd)
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Malignant Solid Tumor
12/24
03/27
KEYNOTE-D35, NCT05438420: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Recruiting
1/2
120
US, RoW
Q702, Pembrolizumab, KEYTRUDA®
Qurient Co., Ltd., Merck Sharp & Dohme LLC
Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
10/25
06/26
KEYNOTE-E45, NCT05394103: Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Recruiting
1/2
130
US, RoW
Q901, KEYTRUDA® (pembrolizumab)
Qurient Co., Ltd., Merck Sharp & Dohme LLC
Advanced Cancer, Metastatic Cancer
12/25
08/26
DS3939-077, NCT05875168: First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Recruiting
1/2
430
Japan, US
DS-3939a
Daiichi Sankyo
Advanced Solid Tumor, Metastatic Solid Tumor
03/26
07/27
U31402-A-U102, NCT03260491: HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer

Checkmark Data from trial for NSCLC
Jan 2021 - Jan 2021: Data from trial for NSCLC
Checkmark Data from trial for EGFRm NSCLC at ESMO 2020
Sep 2020 - Sep 2020: Data from trial for EGFRm NSCLC at ESMO 2020
Recruiting
1
309
Europe, Japan, US, RoW
HER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
Daiichi Sankyo
Non-Small Cell Lung Cancer (NSCLC)
03/26
12/26
NCT04648254: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor

Recruiting
1
78
US
Q702
Qurient Co., Ltd.
Solid Tumor, Advanced Cancer, Metastatic Cancer
12/24
02/25
KEYNOTE-B43, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Calendar Jan 2024 - Dec 2024: Data from TROPION-Lung02 trial for advanced or metastatic NSCLC
Checkmark Interim analysis data from TROPION-Lung02 trial for NSCLC
Aug 2022 - Aug 2022: Interim analysis data from TROPION-Lung02 trial for NSCLC
Active, not recruiting
1
145
Europe, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, KEYTRUDA®, Pembrolizumab, Carboplatin, Cisplatin
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Advanced or Metastatic NSCLC
06/25
06/25
NCT04419532: A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Recruiting
1
40
Canada, Japan, US
DS-1055a
Daiichi Sankyo Co., Ltd.
Solid Tumor, Advanced Cancer, Metastatic Solid Tumor
12/24
12/24
U31402-A-U103, NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Recruiting
1
280
Japan, US, RoW
HER3-DXd, U3-1402, Patritumab deruxtecan, Osimertinib
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
06/25
02/26
NCT06074705: A Study of DS-1471a In Subjects With Advanced Solid Tumors

Recruiting
1
80
Japan
DS-1471a
Daiichi Sankyo Co., Ltd.
Advanced Solid Tumor
06/27
06/27
NCT05769764: A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer

Completed
N/A
225
US
Archival tissue specimen and immunohistochemistry staining
Daiichi Sankyo, Inc.
Non-small Cell Lung Cancer
04/23
04/23

Download Options